S100A8: A Potential Drug Target and Biomarker for Cystic Fibrosis

Target Name: S100A8

NCBI ID: G6279

S100A8

S100A8: A Potential Drug Target and Biomarker for Cystic Fibrosis

Cystic fibrosis (CF) is a chronic progressive disease that affects the respiratory and digestive systems. It is characterized by the production of thick, sticky mucus that clogs the airways and damages the lungs. The disease can also cause digestive problems, such as abdominal pain and malnutrition.

Currently, there are no cure for CF, and treatments are only designed to manage symptoms and improve quality of life. The standard treatment for CF is a combination of antibiotics, vitamins, and supplements. However, these treatments can have significant side effects, and the long-term outcomes for CF patients are often poor.

S100A8 is a protein that is expressed in the lungs and digestive systems of people with CF. It is also a potential drug target and biomarker for CF. Researchers have found that S100A8 is involved in the development and progression of CF, and that it may be a useful target for new treatments.

S100A8 is a member of the S100 family of proteins, which are known for their role in cell signaling. S100A8 is expressed in the lungs and digestive systems of people with CF, and it is involved in the formation of thick, sticky mucus.

Research has shown that S100A8 is involved in the development and progression of CF by regulating the production and degradation of thick, sticky mucus. It also appears to be involved in the regulation of the immune response, which may play a role in the development of CF.

S100A8 may also be a useful biomarker for CF. The thick, sticky mucus that is produced by people with CF can be used as a biomarker for the disease. This mucus is often used as a sample in scientific research, but it can also be used as a diagnostic test for CF.

Research has shown that S100A8 may be expressed in the airways and digestive systems of people with CF, and that it may be a useful target for new treatments. Studies have shown that S100A8 can be reduced in the airways and digestive systems of people with CF, and that this can improve lung function and overall quality of life.

In conclusion, S100A8 is a potential drug target and biomarker for CF. Its involvement in the development and progression of CF and its potential as a biomarker make it an attractive target for new treatments. Further research is needed to fully understand the role of S100A8 in CF and to develop safe and effective treatments.

Protein Name: S100 Calcium Binding Protein A8

Functions: S100A8 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. It can induce neutrophil chemotaxis and adhesion. Predominantly found as calprotectin (S100A8/A9) which has a wide plethora of intra- and extracellular functions. The intracellular functions include: facilitating leukocyte arachidonic acid trafficking and metabolism, modulation of the tubulin-dependent cytoskeleton during migration of phagocytes and activation of the neutrophilic NADPH-oxidase. Activates NADPH-oxidase by facilitating the enzyme complex assembly at the cell membrane, transferring arachidonic acid, an essential cofactor, to the enzyme complex and S100A8 contributes to the enzyme assembly by directly binding to NCF2/P67PHOX. The extracellular functions involve pro-inflammatory, antimicrobial, oxidant-scavenging and apoptosis-inducing activities. Its pro-inflammatory activity includes recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to pattern recognition receptors such as Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). Binding to TLR4 and AGER activates the MAP-kinase and NF-kappa-B signaling pathways resulting in the amplification of the pro-inflammatory cascade. Has antimicrobial activity towards bacteria and fungi and exerts its antimicrobial activity probably via chelation of Zn(2+) which is essential for microbial growth. Can induce cell death via autophagy and apoptosis and this occurs through the cross-talk of mitochondria and lysosomes via reactive oxygen species (ROS) and the process involves BNIP3. Can regulate neutrophil number and apoptosis by an anti-apoptotic effect; regulates cell survival via ITGAM/ITGB and TLR4 and a signaling mechanism involving MEK-ERK. Its role as an oxidant scavenger has a protective role in preventing exaggerated tissue damage by scavenging oxidants. Can act as a potent amplifier of inflammation in autoimmunity as well as in cancer development and tumor spread. The iNOS-S100A8/A9 transnitrosylase complex directs selective inflammatory stimulus-dependent S-nitrosylation of GAPDH and probably multiple targets such as ANXA5, EZR, MSN and VIM by recognizing a [IL]-x-C-x-x-[DE] motif; S100A8 seems to contribute to S-nitrosylation site selectivity

The "S100A8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets